Chang et al. demonstrated that the activation of the ALDOC-NR2F1 axis by PPAR-γ agonists not only enhances the chemotherapeutic efficacy in GBM but also exhibits ALDOC's tumor-suppressive functions by modulating glycolysis 227. Here, ALDOC is linked to neoplasm.